CL2009000608A1 -
Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone from the first to the third phase decreases from 3 mg to 1.5 mg and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 placebo dosage units or no dosage units; pharmaceutical kit.
- Google Patents
Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone from the first to the third phase decreases from 3 mg to 1.5 mg and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 placebo dosage units or no dosage units; pharmaceutical kit.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=41665344&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000608(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma AgfiledCriticalBayer Schering Pharma Ag
Publication of CL2009000608A1publicationCriticalpatent/CL2009000608A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Producto farmacéutico que comprende drospirenona y 17beta-estradiol, combinación que contiene este producto y kit que contiene esta combinación.Pharmaceutical product comprising drospirenone and 17beta-estradiol, combination that contains this product and kit that contains this combination.
CL2009000608A2008-03-132009-03-13
Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone from the first to the third phase decreases from 3 mg to 1.5 mg and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 placebo dosage units or no dosage units; pharmaceutical kit.
CL2009000608A1
(en)
Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone from the first to the third phase decreases from 3 mg to 1.5 mg and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 placebo dosage units or no dosage units; pharmaceutical kit.
DERIVATIVES OF 2,3-DIHYDROIMIDAZO [1,2-C] QUINAZOLINA SUBSTITUTED WITH AMINOALCOHOLES THAT ARE USEFUL TO TREAT HYPERPROLIFERATIVE DISORDERS AND DISEASES ASSOCIATED WITH ANGIOGENESIS
Compounds derived from 17-beta-cyano-18 alpha-homo-19-nor-androst-4-eno; presenting gestagenic and antimineralcorticoid activity; pharmaceutical composition; and use in the treatment of pre-peri-and postmenopausal disorders and premenstrual disorders.
Compounds derived from benzoxazepine condensed with pyrazolyl or imidazolyl, inhibitors of pi3 kinase activity; pharmaceutical composition comprising a compound; and its use in the preparation of drugs for the treatment of cancer.
COMPOUNDS DERIVED FROM 6-OXO-6,7-DIHIDRO-5H-DIBENZO- [B, D] AZEPIN-7-ILO; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF ALZHEIMER OR CANCER DISEASE.
COMPOUNDS DERIVED FROM 1-OXA-3-AZAESPIRO [4.5] DECAN-2-ONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF A FOOD, OBESITY, DEPRESSION DISORDER.
Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone from the first to the third phase decreases from 3 mg to 1.5 mg and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 placebo dosage units or no dosage units; pharmaceutical kit.
Triphasic combined pharmaceutical product with 24 dosage units, where the amount of drospirenone during the three phases is constant and the amount of 17 beta-estradiol increases from 1 mg to 2 mg, in addition to 4 dosage units of placebo or without units of dosage; pharmaceutical kit.
Pharmaceutical kit comprising one or more packaging units comprising 21 to 28 daily active dosing units in which each comprises at least 2 mg of drosperidone, without spoiling us; use of the kit and a pharmaceutical composition comprising drosperidone to prepare a useful medication as a contraceptive.